Clinical Trials E-Booklet Chapter 4: Defining Progression Boehringer Ingelheim
Clinical Trials E-Booklet Chapter 3: Clinical Trial Endpoints Boehringer Ingelheim
Clinical Trials E-Booklet Chapter 2: Elements of a Clinical Trial Boehringer Ingelheim
Clinical Trials E-Booklet Chapter 1: Introduction & Design of a Clinical Trial Boehringer Ingelheim
Webcast: The Evolution of Cancer Therapies Prof. Kenneth O'Byrne
Webcast: The Changing Face of Cancer Dr. James Spicer
Webcast: A guide to cancer clinical trials - From design to data Dr. Susan Mayor & Dr. Frank Fleischer
ErbB-Family Blockade and afatinib*
Angiokinase Inhibition and Nintedanib (BIBF 1120)*
Volasertib* and Polo-like kinase (Plk) inhibition
The Changing Face of Cancer
Source for healthcare professionals: www.inoncology.com* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.